Scholarlink

Background <p>Respiratory Syncytial Virus (RSV) is one of the leading causes of acute lower respiratory tract infections in Colombia, therefore, as no widespread antiviral exists, maternal immunization using RSV prefusion F protein vaccine (RSVpreF) represents a promising strategy. This study aims to evaluate the cost-utility of the RSVpreF maternal vaccine in preventing RSV infections among Colombian infants.</p> Methods <p>We used a Markov model to simulate a Colombian birth cohort over a lifetime horizon, comparing maternal RSVpreF vaccination with no intervention, reflecting the current standard of care in Colombia. The model incorporated RSV-related outpatient visits, hospitalizations, and deaths. We collected data from clinical trials, peer-reviewed literature, and Colombian national health databases. Costs were analyzed from the perspective of the Colombian healthcare system, adjusted to 2024 USD, and we applied a 5% discount rate to both costs and outcomes. We used a willingness-to-pay (WTP) threshold of $ 7,491 per quality-adjusted life year (QALY). Sensitivity analyses, including one-way and probabilistic sensitivity analyses, were performed to evaluate the robustness of the results.</p> Results <p>Maternal RSVpreF vaccination was associated with a reduction of approximately 25,781 RSV-related cases and an increase of 2,315 QALYs. The incremental cost-effectiveness ratio (ICER) was $ 2,322 per QALY, well below the WTP threshold. Sensitivity analyses identified vaccine effectiveness, vaccine cost and RSV hospitalization rates as the primary drivers of cost-effectiveness. The probabilistic sensitivity analysis indicated an 83.5% probability that the intervention would be cost-effective at the established WTP threshold.</p> Conclusion <p>Maternal RSVpreF vaccination is a cost-effective intervention in Colombia, resulting in significant reductions in RSV-related morbidity and mortality, as well as in the economic burden on the healthcare system. The findings support the inclusion of maternal RSV vaccination in national immunization programs, promoting health equity in underserved communities.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cost-utility of respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for disease prevention among colombian infants

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Jaime Ordóñez,
  • Beatriz Ospina

摘要

Background

Respiratory Syncytial Virus (RSV) is one of the leading causes of acute lower respiratory tract infections in Colombia, therefore, as no widespread antiviral exists, maternal immunization using RSV prefusion F protein vaccine (RSVpreF) represents a promising strategy. This study aims to evaluate the cost-utility of the RSVpreF maternal vaccine in preventing RSV infections among Colombian infants.

Methods

We used a Markov model to simulate a Colombian birth cohort over a lifetime horizon, comparing maternal RSVpreF vaccination with no intervention, reflecting the current standard of care in Colombia. The model incorporated RSV-related outpatient visits, hospitalizations, and deaths. We collected data from clinical trials, peer-reviewed literature, and Colombian national health databases. Costs were analyzed from the perspective of the Colombian healthcare system, adjusted to 2024 USD, and we applied a 5% discount rate to both costs and outcomes. We used a willingness-to-pay (WTP) threshold of $ 7,491 per quality-adjusted life year (QALY). Sensitivity analyses, including one-way and probabilistic sensitivity analyses, were performed to evaluate the robustness of the results.

Results

Maternal RSVpreF vaccination was associated with a reduction of approximately 25,781 RSV-related cases and an increase of 2,315 QALYs. The incremental cost-effectiveness ratio (ICER) was $ 2,322 per QALY, well below the WTP threshold. Sensitivity analyses identified vaccine effectiveness, vaccine cost and RSV hospitalization rates as the primary drivers of cost-effectiveness. The probabilistic sensitivity analysis indicated an 83.5% probability that the intervention would be cost-effective at the established WTP threshold.

Conclusion

Maternal RSVpreF vaccination is a cost-effective intervention in Colombia, resulting in significant reductions in RSV-related morbidity and mortality, as well as in the economic burden on the healthcare system. The findings support the inclusion of maternal RSV vaccination in national immunization programs, promoting health equity in underserved communities.

Clinical trial number

Not applicable.